HER2 MUTANT NON-SMALL CELL LUNG CANCER

This adverse event was reported 11 times

These drugs are most commonly taken by patients reporting HER2 MUTANT NON-SMALL CELL LUNG CANCER:

# Drug Count
0 BEVACIZUMAB 6
1 PEMETREXED 6
2 PEMETREXED DISODIUM 6
3 CARBOPLATIN 5
4 TRASTUZUMAB 4
5 AFATINIB 3
6 DOCETAXEL 2
7 DOCETAXEL ANHYDROUS 2
8 ZONGERTINIB 2
9 CISPLATIN 1
See all common drugs associated with HER2 MUTANT NON-SMALL CELL LUNG CANCER

HER2 MUTANT NON-SMALL CELL LUNG CANCER is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ZONGERTINIB 2 0.0120
1 AFATINIB 3 0.0005
2 NERATINIB 1 0.0004
3 RAMUCIRUMAB 1 0.0002
4 PEMETREXED DISODIUM 6 0.0002
5 TRASTUZUMAB 4 0.0001
6 BEVACIZUMAB 6 0.0000
7 CARBOPLATIN 5 0.0000
8 DOCETAXEL 2 0.0000
9 DOCETAXEL ANHYDROUS 2 0.0000
See all drugs enriched for association with HER2 MUTANT NON-SMALL CELL LUNG CANCER